Equity
Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Gain
Pfizer Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Gain increased by 866.7% to $29.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 25.6%, from $39.00M to $29.00M. Over 5 years (FY 2020 to FY 2025), Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Gain shows a downward trend with a -53.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryProfitability
SignalHigher is better
VolatilityVolatile
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates favorable market conditions for the bank's fixed-income portfolio.
Detailed definition
This metric captures the total gross unrealized gains on debt securities classified as either trading or available-for-s...
Peer comparison
Standard disclosure for banks with significant AFS and trading portfolios.
Metric ID:
debt_securities_trading_afs_gross_unrealized_gainHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $126.00M | $16.00M | $14.00M | $8.00M | $38.00M | $26.00M | $304.00M | $51.00M | $7.00M | $16.00M | $6.00M | $2.00M | $6.00M | $55.00M | $8.00M | $39.00M | $87.00M | $2.00M | $3.00M | $29.00M |
| QoQ Change | — | -87.3% | -12.5% | -42.9% | +375.0% | -31.6% | >999% | -83.2% | -86.3% | +128.6% | -62.5% | -66.7% | +200.0% | +816.7% | -85.5% | +387.5% | +123.1% | -97.7% | +50.0% | +866.7% |
| YoY Change | — | — | — | — | -69.8% | +62.5% | >999% | +537.5% | -81.6% | -38.5% | -98.0% | -96.1% | -14.3% | +243.8% | +33.3% | >999% | >999% | -96.4% | -62.5% | -25.6% |
Range$2.00M – $304.00M
CAGR-26.6%
Avg YoY Growth+347.9%
Median YoY Growth-20.0%
Current Streak2 quarters growth
Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Gain at Other Companies
Frequently Asked Questions
- What is Pfizer's debt securities (trading and afs) - accumulated gross unrealized gain?
- Pfizer (PFE) reported debt securities (trading and afs) - accumulated gross unrealized gain of $29.00M in Q1 2026.
- How has Pfizer's debt securities (trading and afs) - accumulated gross unrealized gain changed year-over-year?
- Pfizer's debt securities (trading and afs) - accumulated gross unrealized gain decreased by 25.6% year-over-year, from $39.00M to $29.00M.
- What is the long-term trend for Pfizer's debt securities (trading and afs) - accumulated gross unrealized gain?
- Over 5 years (2020 to 2025), Pfizer's debt securities (trading and afs) - accumulated gross unrealized gain has grown at a -53.5% compound annual growth rate (CAGR), from $138.00M to $3.00M.
- What does debt securities (trading and afs) - accumulated gross unrealized gain mean?
- The total paper gains on debt securities held for trading or available for sale.